Gynecological Presentations Following Supracervical Hysterectomy (GPH)

June 9, 2019 updated by: Ayman S Dawood, MD, Tanta University

Gynecological Presentations and Pelvic Symptoms Following Supracervical Hysterectomy for Benign Pathologies: A Survey Study

Supracervical hysterectomy is widely common and had many complications either immediate or delayed. In these patients bleeding, infection, chronic pelvic pain are common. In these patients cervical biopsy will be done and histopathological examinations will be done to evaluate the pathology in these patients.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

  • Study design and settings: Cross sectional descriptive studies
  • Patients: 130 patients with hysterectomy recruited at Tanta University Hospital, gynecology clinics in central hospitals in Gharbia governorate will be recruited according inclusion and exclusion criteria. Inclusion criteria include all symptomatizing patients following supracervical hysterectomy, of any age, of any complaints. The
  • Methods: All patients' demographic data, history, indication of hysterectomy, duration since operation, postoperative complications and their main complaint.

Study Type

Observational

Enrollment (Actual)

130

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Algharbia
      • Tanta, Algharbia, Egypt, 31111
        • Ayman Shehata Dawood

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

• Patients: 1280 patients with hysterectomy recruited at Tanta University Hospital, gynecology clinics in central hospitals in Gharbia governorate

Description

Inclusion Criteria:

  • Hysterectomy for benign pathologies

Exclusion Criteria:

  • Hysterectomy for malignancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
supracervical hysterectomy
Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix
Filling printed questionnaire + Pelvic examination
Other Names:
  • Pelvic examination

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
number of participant with gynecological symptoms following hysterectomy
Time Frame: 6 months
Symptoms occurring after hysterectomy
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ayman Dawood, Lecturer at Tanta University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2018

Primary Completion (Actual)

March 31, 2019

Study Completion (Actual)

March 31, 2019

Study Registration Dates

First Submitted

July 22, 2018

First Submitted That Met QC Criteria

July 27, 2018

First Posted (Actual)

July 31, 2018

Study Record Updates

Last Update Posted (Actual)

June 12, 2019

Last Update Submitted That Met QC Criteria

June 9, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • GPHysterectomy

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Patients data are not allowed to be public

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gynecological Survey

3
Subscribe